Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry (Q40791761)

23 September 2017

Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry (English)

1 reference

23 September 2017

1 reference

6

1 reference

23 September 2017

3

Ralf Dechend

1 reference

23 September 2017

9

Roland E Schmieder

1 reference

23 September 2017

Iris Kistner

1

1 reference

23 September 2017

Uwe Zeymer

2

1 reference

23 September 2017

Ina Hagedorn

4

1 reference

23 September 2017

Thomas Riemer

5

1 reference

23 September 2017

David Pittrow

7

1 reference

23 September 2017

Jochen Senges

8

1 reference

23 September 2017

20 April 2016

1 reference

Journal of Clinical Hypertension

23 September 2017

1 reference

23 September 2017

18

1 reference

23 September 2017

1045-1053

1 reference

23 September 2017

10

1 reference

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

23 September 2017

1 reference

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

21 January 2018

1 reference

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis

21 January 2018

1 reference

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial

21 January 2018

1 reference

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

21 January 2018

1 reference

Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry

21 January 2018

1 reference

Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy.

21 January 2018

1 reference

Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring

21 January 2018

1 reference

Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus

21 January 2018

1 reference

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

21 January 2018

1 reference

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial

21 January 2018

1 reference

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JCH.12828

1 reference

23 September 2017

0 references

1 reference